← Back

Clearpoint Neuro Inc

ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Price · split & dividend adjusted
News & notes moving CLPT
CLPT▼

ClearPoint Neuro lowers 2026 revenue guidance to $48 million to $52 million

ClearPoint Neuro has revised its 2026 revenue guidance to between $48 million and $52 million, down from the prior range of $52 million to $56 million, as it shifts investment toward clinical readiness, its CAL preclinical facility, and a focused ultrasound partnership. President and CEO Joseph Burnett said faster partner regulatory timelines have elevated the need for commercial readiness activities, prompting the company to prioritize clinical case support, global regulatory expansion, and development of focused ultrasound robotics and Harmony software over traditional sales expansion. The company reported second-quarter 2026 revenue of $10.9 million with a gross margin of 62%, while cash and cash equivalents stood at $29.4 million as of June 30, 2026, reflecting an operational cash burn of $15 million through the first half of the year. CFO Danilo D’Alessandro noted that biologics and drug delivery revenue fell 15% to $4 million, neurosurgery navigation revenue grew to $5.6 million, and capital equipment and software revenue increased 24% to $1.3 million. Management expects operational cash burn to decrease in the second half as the IRRAS integration completes, and Burnett expressed confidence in scaling, citing more than 30 trained clinical specialists and a new CAL facility that could surpass $60 million in annual capacity.
CLPT ▼
Seeking Alpha·23dRead more ▾
Biotech & Genomic Medicine▲

ClearPoint Neuro shares surge 26% on partner uniQure's regulatory milestone

ClearPoint Neuro shares rallied 26% in the last trading session to close at $16.81 on heavy volume. The surge was driven by investor optimism after partner uniQure announced a regulatory milestone for its Huntington's disease treatment candidate AMT-130, with three-year Phase I/II data potentially supporting a Biologics License Application for accelerated approval. ClearPoint Neuro is expected to report a quarterly loss of $0.27 per share on revenues of $13 million, up 41% year-over-year. The stock carries a Zacks Rank of 3, or Hold.
QURE ▲CLPT ▲
Biotech & Genomic Medicine ▲
Zacks Investment Research·69dRead more ▾
Biotech & Genomic Medicine▲

uniQure Leads Biotech Gainers After FDA Softens Stance on Gene Therapy

uniQure led a group of biotech gainers on Wednesday after the FDA softened its stance on the company’s investigational gene therapy AMT-130 for Huntington’s disease. The agency now considers the 3-year analysis from the Phase I/II study acceptable as the primary basis for a Biologics License Application for accelerated approval, reversing its earlier recommendation for a prospective, randomized, double-blind, sham-surgery-controlled study. uniQure intends to submit the BLA in the third quarter of 2026, and its shares closed at $48.16, up 78.44%. Other notable movers included Elicio Therapeutics, which rose 70.65% after reporting that three advanced pancreatic cancer patients in its Phase 2 AMPLIFY-7P study achieved complete responses following treatment with its vaccine ELI-002 7P and subsequent checkpoint inhibitor therapy. Lunai Bioworks gained 40.06% after its CEO outlined developments including a first revenue-generating U.S. government defense contract and the formation of the Pathfinder Consortium. ClearPoint Neuro climbed 26.01% on spillover optimism related to uniQure’s AMT-130, which is administered using ClearPoint’s navigation system. Polyrizon added 15.55% after the publication of a U.S. patent application for its nasal drug delivery technology, and Faeth Therapeutics rose 14.59% as it anticipates topline data from a Phase 2 trial of its lead candidate PIKTOR in advanced endometrial cancer in the second half of 2026.
ELTX ▲LNAI ▲PLRZ ▲QURE ▲CLPT ▲FTH
Biotech & Genomic Medicine ▲
RTTNews·70dRead more ▾
Biotech & Genomic Medicine

Biotech Companies Advance Regulatory and Commercial Milestones Across Multiple Therapeutic Areas

Several biotechnology companies reported significant regulatory, clinical, and commercial developments this week. NeOnc Technologies Holdings received Investigational New Drug authorization from the Department of Health – Abu Dhabi for NEO212, its oral brain tumor therapy, marking the first international regulatory clearance for the program. uniQure announced that the FDA indicated its Phase I/II data could support a Biologics License Application for accelerated approval of AMT-130 in Huntington's disease, with submission planned for the third quarter of 2026. IceCure Medical reported a 70% increase in its active U.S. commercial install base for the ProSense breast cancer cryoablation platform since receiving FDA clearance in October 2025. ClearPoint Neuro expanded its brain drug delivery ambitions through a 10-year focused ultrasound development partnership with Sungkyunkwan University in South Korea.
NTHI ▲QURE ▲ICCM ▲CLPT
Biotech & Genomic Medicine
GlobeNewswire·70dRead more ▾
© 2026 MarketDXAsset